These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26627251)

  • 21. WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells.
    Elmaagacli AH; Koldehoff M; Peceny R; Klein-Hitpass L; Ottinger H; Beelen DW; Opalka B
    Haematologica; 2005 Mar; 90(3):326-34. PubMed ID: 15749664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
    Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study on the treatment of the p15 gene combined with Bcr-abl-specific siRNA and STI571 for chronic myeloid leukemia.
    Wang W; Du Y; Li NN; Lv FF; Lin GQ
    Genet Mol Res; 2014 May; 13(2):4089-101. PubMed ID: 24938701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi).
    Wilda M; Fuchs U; Wössmann W; Borkhardt A
    Oncogene; 2002 Aug; 21(37):5716-24. PubMed ID: 12173041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Inhibitory effect of RNA interference on chronic myeloid leukemia bcr/abl oncogene expression].
    Ma XX; Wang C; Wei J; Qin YW; Yan SK; Gao YR; Cai Q
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):359-62. PubMed ID: 16185484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short interfering RNA (siRNA) as a novel therapeutic.
    Pushparaj PN; Melendez AJ
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):504-10. PubMed ID: 16700886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Engineering of small interfering RNA-loaded lipidoid-poly(DL-lactic-co-glycolic acid) hybrid nanoparticles for highly efficient and safe gene silencing: A quality by design-based approach.
    Thanki K; Zeng X; Justesen S; Tejlmann S; Falkenberg E; Van Driessche E; Mørck Nielsen H; Franzyk H; Foged C
    Eur J Pharm Biopharm; 2017 Nov; 120():22-33. PubMed ID: 28756280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
    Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
    Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
    Kim JE; Yoon S; Choi BR; Kim KP; Cho YH; Jung W; Kim DW; Oh S; Kim DE
    Leukemia; 2013 Aug; 27(8):1650-8. PubMed ID: 23434731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting leukemic fusion proteins with small interfering RNAs: recent advances and therapeutic potentials.
    Thomas M; Greil J; Heidenreich O
    Acta Pharmacol Sin; 2006 Mar; 27(3):273-81. PubMed ID: 16490161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Construction of eukaryotic expression vector of siRNA specific to bcr/abl fusion gene].
    Xi YM; Liu T; Meng WT; Wang YH; Gu L; Lu XX; Gong YP
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Jul; 36(4):460-3. PubMed ID: 16078560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes).
    Wu Y; Yu L; McMahon R; Rossi JJ; Forman SJ; Snyder DS
    Hum Gene Ther; 1999 Nov; 10(17):2847-57. PubMed ID: 10584930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of vascular endothelial growth factor (VEGF) expression by targeting the Bcr-Abl oncogene and protein tyrosine kinase activity in Bcr-Abl-positive leukaemia cells.
    Li L; Zhang R; Fang ZY; Chen JN; Zhu ZL
    J Int Med Res; 2009; 37(2):426-37. PubMed ID: 19383237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of bcr-abl mRNA by chemically modified siRNA.
    Murao S; Diala I; Fujii M
    Nucleic Acids Symp Ser (Oxf); 2008; (52):499-500. PubMed ID: 18776472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of siRNAs in combination with Gleevec on K-562 cell proliferation and Bcr-Abl expression.
    Baker BE; Kestler DP; Ichiki AT
    J Biomed Sci; 2006 Jul; 13(4):499-507. PubMed ID: 16547768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific killing of Ph+ chronic myeloid leukemia cells by a lentiviral vector-delivered anti-bcr/abl small hairpin RNA.
    Li MJ; McMahon R; Snyder DS; Yee JK; Rossi JJ
    Oligonucleotides; 2003; 13(5):401-9. PubMed ID: 15000831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells.
    Zhang JH; He YL; Zhu R; Du W; Xiao JH
    Tumour Biol; 2017 Jun; 39(6):1010428317713394. PubMed ID: 28639894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation.
    Rangatia J; Bonnet D
    Leukemia; 2006 Jan; 20(1):68-76. PubMed ID: 16281073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RNA interference--about the reality to be exploited in cancer therapy.
    Bakalova R
    Methods Find Exp Clin Pharmacol; 2007; 29(6):417-21. PubMed ID: 17922071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.